Takeda shareholders approve $59 billion Shire buy but are wary of debt load

Takeda buying Shire
– Takeda’s deal to buy London-listed Shire is the biggest overseas acquisition by a Japanese company.
– It’s also one of the most indebted, with the company having secured $30.9 billion in bank loans.
– Takeda shares have fallen 25 percent since it revealed interest in buying Shire — they closed up 1 percent at on Wednesday.

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.

Takeda will be joining the ranks of the world’s top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company.